#entyvio

[colitisconfessions]

Short but kinda long update;

After being in remission with Remicade until 2020, I’ve been on Stelara (we thought was working but then immediately wasn’t), then switched to Humira biosimilar called Amgevita which never worked, but last scope in January of 2022 didn’t show enough inflammation to warrant a medication change. Tuesday I had a flexi-sig that showed significant inflammation so we are now in the process of starting Entyvio. I am really hoping and praying that this is it - I miss what life was like on Remicade, until I broke through. I don’t even know what I’ll do if life is like that again. I’ve just been flaring or on prednisone for the last three years.

I know everyone is so different, but if anyone has any advice, tips, tricks etc regarding Entyvio I would appreciate it - but please be gentle with me I’m not really in a place to accept failure stories right now.

[notaccurateornice]

My first four entyvio infusions are scheduled, here’s hoping they work because none of the conventional treatments for my UC have worked.

[adelaidedrubman]

INSURANCE APPROVED STELARA EPIC WIN

[primarining]

when the shit is so bad you can feel the life flush from your face

[pelipper]

Alright, time to pregame for my infusion by taking some Prednisone and Benadryl. 🤙

[mey-rin-is-fabulous]

Okay as anyone who’s been around for any amount of time since 2021 knows I have colitis. And I’m gonna run through everything that happened before and after my diagnosis. Under a read more to save your dashes.

I first started having problems after easter 2014. Constant diarrhea and constipation and it was switching between the two constantly. It started off by me only having bowel movements every three days and I found my bathroom usage got worse after either eating high fiber foods or pizza. And as I kept going through highschool it got worse and worse, I had a hard time going to school and staying in class, my guts were constantly churning and accidents were not uncommon. All throughout this I had no idea what I was experiencing was a bowel disease, I just figured it’d clear up eventually. 

My mom and me thought it was a diet thing, so we tried adding more electrolytes, these blueberry smoothies and I tried to add yogurt. None of it helped. So now we’re coming up to late 2018 the end of my highschool career and start of my failed college career. I went to my doctor, he sent me to a specialist. I filled out a form, said specialist told me to just take metamucil, I thought that was the end of it. It wasn’t the metamucil did nothing.

2019 I was still experiencing problems. Went back to my doctor, said hey I think this specific type of food is setting this off. My doctor agrees that I should cut it out. I find out on my own somewhere along all of this about the gluten free diet and celiac disease. So I decide to go gluten free, it helps.

2020 since our family doctor retired me and my mom go see a satellite doctor, a small little cubicle in our local pharmacy with a nurse practitioner and the doctor on video call. I tell him about the problems I’ve been experiencing and he writes up a recommendation to send to a specialist.

Late 2021 I receive a call from said specialist, I have been scheduled for a colonoscopy early 2022. Colonoscopy gets pushed back a month from late January to early February. I go for my colonoscopy and after I am told that I have ulcerative colitis. I was prescribed an enema for like 2 weeks and mezavant(big pills we started at like 4 daily) which was constant. After that I had to get a TB test to make sure nothing would affect any current or future medications. Went back in March for a sigmoid( get yourself knocked out never do it while awake.) We scheduled another sigmoid for May, this time I would be knocked out for it, things were looking better. Also throughout this whole time, I was getting bloodwork off and on. Went into my doc’s office in September and my levels were looking good but around that time I accidentally had non GF spaghetti. After September things got rough for me again.

Now in early 2023, I had my first sigmoid of the year in April. My doc told me instead of ulcerative colitis it was looking more like chron’s colitis. I was told to stop taking my mezavant and was instead prescribed a steroidal medication as well as calcium tablets and vitamin d tabs. I was also prescribed another steroidal medication that required constant bloodwork. About a week or two on the new meds I was told to stop taking the new steroidal meds because my liver enzymes were up. Makes sense because I was extremely sick and after I stopped taking the medication I started feeling better. Saw my doc again end of June so now we’re in July and I’m getting a chest x-ray done this Friday and if everything’s good probably starting my new medication treatment after. the medication is delivered through IV but can be given through a needle injection after, it’s called entyvio.

[allmediconline23]

 Buying Entyvio Online

Living with a chronic illness can be challenging, particularly when it comes to managing medications. However, advancements in technology and online platforms have made it easier than ever to access necessary treatments.We provide quality Entyvio® supplies direct from manufacturers worldwide at an affordable price. As a top-rated international wholesale Entyvio® supplier, we work with a lot of different clients, from hospitals and doctors to independent clinics.

[mypokemonranch]

It feels so good to be back home after surgery! ❤️‍🩹

I had a bowel resection and end ileostomy last week after dealing with an obstruction earlier this year. I started on biologics back in 2021, but unfortunately Humira wasn't enough to keep my Crohn's in remission because I started producing antibodies against it. Since my insurance took their sweet time approving Entyvio, I ended up with a bowel obstruction in March which almost resulted in an emergency surgery.

Thankfully, I was able to recover at home after narrowly avoiding emergency surgery. I was on TPN and a full liquid diet for a month and a half until my body was ready for surgery. I was told that I had to have a temporary ileostomy, but to me that was a small price to pay if it meant I could achieve remission for the first time in years.

Surgery went well, and although my in-patient stay was bumpy at times due to some nausea and vomiting, I'm feeling a lot better than I felt before surgery. My pain is controlled pretty well right now, and I have a follow-up appointment with my surgeon and my regular gastroenterologist in a few weeks. I should be having my ileostomy reversal surgery by the end of summer!

I'm hoping that by the end of this ordeal I'll be able to have a good few years of remission from Crohn's Disease. This disease sucks so much and has taken so much out of me. But no matter what life throws at me, I'm not going to give up without a fight. 💪✨

[chronically-crying]

One time before I even got sick I said (mostly joking) to my mom and sister that the American healthcare system has a personal vendetta against me (I have now been cucked by blue cross blue shield, COBRA, PrefferedOne, and for both lifesaving and not strictly necessary medical things) and my sister's response was "IDK the American healthcare system hasn't been particularly kind to me either" (she had a broken leg that needed surgery but she had to come home and wait several days before she actually went back and got the metal screws in her leg that she needed for the bones to heal properly)

but joke's on her because no I have been 1) in preauthorization hell for HRT for 3 full months (my gender care doc had never seen it takes that long) 2) I had a full psych eval scheduled bc I suspect I have ADHD and a psychiatrist I saw was like "yeah you should probably get the whole deal" and it was cancelled the day before, 3) I got diagnosed with IBD, given 2 months worth of Prednisone and told "you'll see someone in 6 weeks" only for the appointment to cancel the day of bc I was 17 and they weren't licensed for peds, 4) I've been on 3 different biologics now for IBD, Remicade which barely worked, Entyvio which did not work, and now Stelara which is great. IF ONLY MY INSURANCE LET ME HAVE IT because reauthorization came around in March and it got denied and ever since I have been living on the edge of a Crohn's flare

BONUS: this isn't insurance related but I got a fancy rare skin condition called pyoderma gangrenosum (DONT GOOGLE THIS ITS HORROR MOVIE SHIT) which is heavily related to Crohn's but because of how it presents it doesn't totally seem like an autoimmune condition and I was treated for the wrong thing from mid-May to the end of July before someone went "have you seen a dermatologist yet? Bc this is definitely not an infection" and I basically suffered for 7 weeks for no reason

[appalachianoracle]

I don’t know how to tell people I’m not okay because in my head it’s entirely my own responsibility to take care of my mental health. Others have their own issues. And I don’t want others to have to use their personal time and energy trying to make me feel better. I know that’s what friends and support systems are for. But I feel so bad burdening others.

I need my insurance to stop being a dick. I need them to give me my entyvio so I can get out of this flare and get off this high dose of prednisone that is slowly driving me to madness and not in a hyperbolic way. As in I have had to make a pact to not unalive myself for the sake of those around me despite the fact that existence is very spicy and I’m very tired of it all.

I’m tired of being in pain. I’m tired of being an emotional mess because all these things are outside of my control. There is no solution or end in sight. Some days it’s easier to exist, but its never just easy.

But I guess maybe life isn’t easy for anyone. We all have something we’d rather not experience but can’t control. I wish I knew what the difference is between someone who can handle it and someone who can’t besides the outcome.

The universe is a mystery to me in that aspect. I’m still here. I don’t know how. I know I’ll be okay and that ultimately none of my worries matter in the grand scheme of things because I know how the story ends no matter what choice I make. At least I’m comfortable enough with death and mortality to be chill with that.

These are just void thoughts. Thoughts I need to get off my chest that *someone* might see and understand silently. Cause there’s something comforting about the idea that even one little stranger might see the thoughts and be like “Ah yes same.” While also not having to state aloud.

Cause I could just write these on paper and burn them. But that doesn’t bring the same sense of peace that voiding thoughts on an obscure platform that most people don’t know me on.

[pernlover]

Infusion day. Thank goodness for Entyvio which keeps me sorta functional.

[marketsndata]

Global Inflammatory Bowel Disease Market Size, Share, Growth and Forecast 2031

Global inflammatory bowel disease market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 22.07 billion in 2023 to USD 32.98 billion in 2031. The market demand for Inflammatory Bowel Disease is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.

Inflammatory Bowel Disease is a chronic inflammatory condition of the gastrointestinal tract. It includes two types: Ulcerative colitis and Crohn’s disease. Ulcerative colitis causes swelling and sores in the colon and rectum. Moreover, Crohn’s disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and anus. Common inflammatory bowel disease symptoms include abdominal pain, diarrhea (sometimes with blood), weight loss, rectal bleeding, fever, anemia, anxiety and depression. The diagnostic process for IBD involves multiple approaches. Clinicians typically start with a detailed medical history and physical examination. Some of the associated procedures include blood tests to evaluate anemia or inflammation, stool tests to exclude infection, and imaging studies such as CT scans or MRIs. The diagnosis is typically established through endoscopic procedures, namely colonoscopy, which permits direct visualization of the mucosal surfaces of the intestinal tract and tissue samples (biopsies) taken for further examination. For instance, as per a systematic review article published on 17 June 2024, reported that the incidence rate of Ulcerative Colitis and Crohn’s Disease in the European region is approximately 24.3 and 12.7 per 100,000, respectively. The annual incidence rates for Ulcerative Colitis and Crohn’s Disease in North America were reported at 19.2 and 20.2 per 100,000 individuals annually. The incidence of IBD in Asia ranges from 0.5 to 3.4 per 100,000 individuals, signifying the dynamic changing face of this emerging disease condition in the region. Incidence has risen over the past 10–15 years in Korea, Japan, China, Hong Kong, and India. The increase was more impressive in countries adopting a Western industrialized lifestyle.

Increase in the Prevalence of Inflammatory Bowel Disease

The increase in the prevalence of Ulcerative colitis and Crohn’s disease is anticipated to fuel the growth of the inflammatory bowel disease market. Increasing inflammatory bowel disease is now emerging as a public health problem that is increasingly taking over industrialized nations. Several causes exist for the increase in this disease, with one significant cause being lifestyle changes: diets high on processed foods and low in fiber negatively impact health and gut health. In addition, the hygiene hypothesis provides an insight revealing that lower exposure to infections in the childhood period shows increased risk factors for autoimmune diseases, such as IBD. An urgent need to do further research into causes and treatments of IBD is a critical reason for the greater number of diagnosed cases. Public education campaigns are also needed towards communities about IBD for early detection and proper management of the disease. Considering that more people are living with the burden of IBD, managing this chronic illness needs a collective effort by providers, researchers, and policymakers to give better care and support to affected patients. For instance, in April 2024, Takeda Pharmaceutical Company Limited received approval from the U.S. Food and Drug Administration for ENTYVIO (vedolizumab) subcutaneous (SC) administration for the treatment in adults with moderately to severely active Crohn’s disease (CD).

Advancements in the Treatment Options for Inflammatory Bowel Disease

Advancements in the treatment of inflammatory bowel disease include a wide approach to managing this chronic condition, such that patients are offered more effective and targeted therapies. Indeed, biologics, which target inflammatory pathways by specifically targeting cells, pathways, or molecules that contribute to inflammation, have revolutionized the management of this disease, from addressing underlying pathogenic mechanisms to the historical approach of symptom relief. Moreover, biologics like anti-TNF agents and integrin inhibitors have also proven useful in many patients’ induction and maintenance of remission. New small molecules and JAK inhibitors are also emerging as additional alternatives in some cases. Personalized medicine has also advanced the ability of doctors to treat individual patients according to their individual genetic makeup and disease characteristics, thus offering a better chance for positive outcomes. Continued research and clinical trials are discovering additional new therapeutic targets, as well as new combination therapies, promising higher efficacy and safety. For instance, on 19 February 2024, Pfizer Inc. received approval from the European Commission (EC) granting marketing authorization for VELSIPITY (etrasimod) to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or was intolerant to either conventional therapy or a biological agent. VELSIPITY is the first and only advanced oral ulcerative colitis treatment approved for use in patients 16 years of age.

Crohn’s Disease Segment to Dominate the Inflammatory Bowel Disease Market

The Crohn’s disease segment dominates the inflammatory bowel disease market due to the high prevalence and the specific need for treatment. Often, Crohn’s disease affects any part of the gastrointestinal tract and generally causes more severe and varied symptoms than ulcerative colitis does, so its requirements are more complex, thus dictating a wide range of treatment options, including biologics, immunosuppressants, and emerging therapies tailored according to the needs of the individual patient. Other drivers for the growth of this segment include improved diagnosis techniques and increased awareness. Research and clinical studies in Crohn’s disease continue to drive ongoing innovations and therapies that improve patient outcomes significantly, thus driving growth in the market. Also, with healthcare providers seeking more practical treatments for this chronic condition, the Crohn’s disease market is poised to capture a greater share of the inflammatory bowel disease market. For instance, on 18 May 2023, AbbVie Inc. received approval from the U.S. Food and Drug Administration for RINVOQ (upadacitinib) to treat adults with moderate to severely active Crohn’s disease.                                                                                                                          

North America Dominates Inflammatory Bowel Disease Market                          

North America dominates the Inflammatory Bowel Disease (IBD) market, primarily driven by a combination of high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development. The incidences of ulcerative colitis in North America range from 2.2 to 19.2 cases per 100,000 person-years, and Crohn’s disease incidences range from 3.1 to 20.2 cases per 200,000 person-years. In the United States the prevalence of adult ulcerative colitis was 238 per 100,000 population and 201 per 100,000 population with data from a large study based on insurance claims. Inflammatory bowel disease is more prevalent in North America and Europe than in Asia or Africa. The region has a well-established healthcare system that makes it easier to administer new, advanced therapies such as biologics and emerging medications specifically designed to meet the needs of each patient. Well-organized awareness programs and support groups help facilitate earlier diagnosis and optimal management of the disease. For instance, on August 12, 2024, Celltrion USA, Inc. (Celltrion USA) received approval from the Food and Drug Administration for biosimilar adalimumab-aaty. Adalimumab-aaty is approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease and Ulcerative colitis. The treatment for self-funded employer plans was available in the U.S. from Costco Specialty Pharmacy on October 1, 2023.

Download Free Sample Report

Future Market Scenario (2024-2031F)

The future market scenario seems promising for the inflammatory bowel disease market, influenced by factors that increase demand and investment in this market. The inflammatory bowel disease market is full of promise with the continuous advancement in research, technology, and options available for treatment. Moving into the future, with an increased understanding of the mechanisms driving IBD, more targeted therapies are emerging, such as biologics and small molecules targeting some of the pathways responsible for inflammation. In addition, the increasing incidence of IBD in emerging markets and globally will increase the patient population, which requires effective management systems. Improved diagnosis and early detection methods will ensure timely interventions, which will be beneficial to the patients and improve their quality of life. Other factors that will drive innovation in the field are stronger investment in research and more collaboration between pharmaceutical companies and academic institutions. For instance, on 4 October 2023, Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, the two types of inflammatory bowel disease.

Report Scope

“Inflammatory Bowel Disease��Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global inflammatory bowel disease market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/inflammatory-bowel-disease-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[sakuramom]

Cue the joint pain thank you entyvio very cool

[bidhuan]

FDA baru-baru ini mengumumkan persetujuan vedolizumab (Entyvio, Takeda) subkutan (SC) untuk terapi pemeliharaan, untuk mengobati penyakit Crohn

Majalah Farmasetika – Persetujuan Entyvio subkutan dalam [CD] memenuhi tujuan kami untuk menyediakan pilihan pengobatan yang dapat membantu pasien mencapai remisi kolitis ulserativa atau [CD]-nya, sambil memberikan fleksibilitas dan pilihan rute administrasi. Dengan Entyvio Pen, pasien memiliki opsi untuk memberikan pengobatan pemeliharaan mereka di rumah atau saat bepergian,” kata Brandon Monk,…

[primarining]

man I got a taste of what it's like to not be in agony and having to deal with my intestines every single day and then the meds stopped working and now my health is backsliding yay!!!!!!!!!!!!!!!!!!!!!!!!! I'm not unfathomably angry and tired

[pelipper]

It's Entyvio infusion day! 💪🔥